NCT06906861View on ClinicalTrials.gov

Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal

CompletedOBSERVATIONAL

Enrollment

284

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 10, 2024

Study Completion Date

November 10, 2024

Conditions

Epistaxis

Trial Locations (1)

+977

IOM, Kathmandu

All Listed Sponsors

lead

Institute of medicine, Maharagjung medical campus

OTHER

NCT06906861 - Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal | Biotech Hunter | Biotech Hunter